ES / EN
- July 3, 2025 -
No Result
View All Result
OnCubaNews
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
OnCubaNews
ES / EN
Home World

China approves patent for COVID-19 vaccine still on the testing phase

The Phase II results of the vaccine’s clinical trials showed that it is safe, it induces an immune response against the coronavirus, and it could "be mass-produced in a short time".

by
  • Rosana Berjaga
    Rosana Berjaga,
  • Dunia Cruz
    Dunia Cruz
August 18, 2020
in World
0
Chinese scientists are working on researching a vaccine against COVID-19. Photo: Shepherd Hou / EFE / Archive.

Chinese scientists are working on researching a vaccine against COVID-19. Photo: Shepherd Hou / EFE / Archive.

Help us keep OnCuba alive

The State Intellectual Property Office of China (SIPO) approved the first patent for a COVID-19 vaccine candidate – still in the third phase of clinical trials – that could ‘be mass-produced in a short time”, showed the local press this Monday.

This vaccine, developed by the Military Scientific Institute and the Chinese biopharmaceutical company CanSino Biologics, began to be used in late June in the Chinese Army after a team led by researcher Chen Wei discovered a highly efficient neutralizing monoclonal antibody.

The results of the second phase of clinical trials of the vaccine showed that it is safe and induces an immune response against the coronavirus, according to research published at the end of July in The Lancet.

According to the SIPO patent, the vaccine has shown a “good immune response in mice and rodents, and it can induce the body to produce a strong cellular and humoral immune response in a short time”, reports the Cantonese newspaper Southern Metropolis.

The patent claims that this vaccine “can be mass-produced in a short time”, and that it is “quick and easy to prepare”. Its safety and effectiveness must be confirmed in phase three, which takes place abroad, the information adds.

Related Posts

Photo: ABC.

All the president’s refugees

June 13, 2025
View of Pope Francis’s tomb in the Basilica of Santa Maria Maggiore in Rome. Photo: EFE/Vatican Press/Francesco Sforza.

Aurelio Alonso on the Pope: “Francis as a name meant a lot from the beginning”

May 4, 2025
April 23, 2025, photo of U.S. President Donald Trump signing executive orders in the Oval Office of the White House. Photo: EFE/EPA/Samuel Corum/Pool.

The ups and downs of the humanitarian parole

April 30, 2025
A screen shows the fall of the Dow Jones Industrial Average at the close of trading at the New York Stock Exchange in New York, USA, on April 4, 2025. Photo: Justin Lane/EFE/EPA.

Trump calls on Americans to “hang tough” and says his tariffs are an “economic revolution”

April 7, 2025

OMS dice tener “buenas noticias” sobre vacuna contra COVID-19

On the other hand, experts quoted by the Global Times newspaper indicate that the patents’ granting demonstrates the “originality and creativity” of the vaccine, and that “it is likely that CanSino will also apply for a patent together with foreign authorities in order to protect its intellectual property rights during international cooperation”.

Research published in The Lancet (in July) reported that more than 500 people were tested as a continuation of the first tests published last May, also with positive results, but that more phase III human trials will be needed to confirm whether this vaccine candidate effectively protects against SARS-CoV-2 coronavirus infection.

However, the authors highlighted that no participant in phase two of the trials was exposed to the virus after vaccination, so it is not yet possible to determine whether the vaccine candidate effectively protects against SARS-CoV-2 infection.

Rusia produce la primera partida de su vacuna anti-COVID-19 Spútnik V

The vaccine candidate uses a weakened virus from the common cold – Adenovirus type 5, Ad5-nCoV – to deliver genetic material. In total, the second phase of testing of this vaccine involved 508 participants.

CanSino Biologics developed together with the Chinese Military Academy of Sciences a vaccine against the Ebola virus that obtained a provisional license in 2017. The company was created in 2009 in the northeastern city of Tianjin, and focuses mainly on the development and production of vaccines.

The period for a vaccine to be available for mass use is typically at least 12 to 18 months, according to the World Health Organization (WHO), although China has accelerated the processes due to the global health emergency and it has allowed some studies in several phases to be carried out at the same time.

 

  • Rosana Berjaga
    Rosana Berjaga,
  • Dunia Cruz
    Dunia Cruz
Tags: ChinacoronavirusCOVID-19 vaccine
Previous Post

Study Finds Viruses Can Spread Through Dust

Next Post

Cuba sends a new team to Venezuela to fight COVID-19

Rosana Berjaga

Rosana Berjaga

Dunia Cruz

Dunia Cruz

Next Post
Cuban doctors in Venezuela. Photo: elestimulo.com / Archive.

Cuba sends a new team to Venezuela to fight COVID-19

The quarantine for Cubans, in 7minutes

Julio Trigo Hospital, in Havana. Photo: cubacons.cu.

Havana hospital to become COVID-19 isolation and care center

Leave a Reply Cancel reply

The conversation here is moderated according to OnCuba News discussion guidelines. Please read the Comment Policy before joining the discussion.

Your email address will not be published. Required fields are marked *

Most Read

  • The Enchanted Shrimp of the Cuban Dance

    3056 shares
    Share 1222 Tweet 764
  • Private sector and tourism in Cuba. Why not?

    10 shares
    Share 4 Tweet 3
  • CIA documents revealing attempts to assassinate Fidel and Raúl Castro declassified

    45 shares
    Share 18 Tweet 11
  • A sanctuary for jazz in Cuba: César López’s dream

    8 shares
    Share 3 Tweet 2
  • Heidy Sánchez after two months without hugging her daughter: “There’s nothing concrete to resolve the case”

    7 shares
    Share 3 Tweet 2

Most Commented

  • Photo: Kaloian.

    Private sector and tourism in Cuba. Why not?

    10 shares
    Share 4 Tweet 3
  • About us
  • Work with OnCuba
  • Terms of use
  • Privacy Policy
  • Moderation policy for comments
  • Contact us
  • Advertisement offers

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

No Result
View All Result
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}